---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-046419"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:36:11.401402+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ABVC licenses MDS drug BLEX 404 to OncoX; eligible for $13.75M in fees plus royalties

## Summary
- ABVC and subsidiary BioLite grant OncoX exclusive rights to develop/commercialize BLEX 404 for MDS in 50% of global markets for 20 years.
- Upfront license fee of $12.5M (cash or OncoX shares) due in 30 days; additional $1.25M milestone after OncoX's next fundraising (no guarantee).
- ABVC entitled to 5% royalties on net sales, capped at $12.5M, after product launch (uncertain).
- BLEX 404 is a β-glucan extract from Maitake mushroom; FDA has approved four INDs for ABVC's oncology pipeline including ABV-1702 for MDS.
- No guarantee any fees or royalties will be received; partnership is early-stage and contingent on OncoX's fundraising and commercial success.

## SEC filing metadata
- accession: 0001213900-24-046419
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/0001213900-24-046419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/ea0206790-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-046419
- JSON: https://secwatch.observer/filing/0001213900-24-046419.json
- Plain text: https://secwatch.observer/filing/0001213900-24-046419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.